CoChat

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where synaptic loss and reduced synaptic integrity are important neuropathological substrates. Neuronal Pentraxin 2(NPTX2) is a synaptic protein that drives the GABAergic inhibitory circuit. Our aim was to examine if NPTX2 cerebral spinal fluid (CSF) levels in DLB patients were altered and how these levels related to other synaptic protein levels and to cognitive function and decline. Methods: NPTX2, VGF, and α-synuclein levels were determined in CSF of cognitive healthy (n = 27), DLB (n = 48), and AD (n = 20) subjects. Multiple cognitive domains were tested, and data were compared using linear models. Results: Decreased NPTX2 levels were observed in DLB (median = 474) and AD (median = 453) compared to cognitive healthy subjects (median = 773). Strong correlations between NPTX2, VGF, and α-synuclein were observed dependent on diagnosis. Combined, these markers had a high differentiating power between DLB and cognitive healthy subjects (AUC = 0.944). Clinically, NPTX2 levels related to global cognitive function and cognitive decline in the visual spatial domain. Conclusion: NPTX2 CSF levels were reduced in DLB and closely correlated to decreased VGF and α-synuclein CSF levels. CSF NPTX2 levels in DLB related to decreased functioning in the visual spatial domain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells10010038

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 NPTX2 levels and relation to biomarkers in CSF. (A): Levels of NPTX2 in CSF of SCD subjects and DLB and AD patients. Box-plots are median and interquartile ranges, whiskers are 95% percentiles. When significant, the p-value of Kruskal–Wallis with post-test is indicated. (B): 3D plot of the levels of the three related synaptic markers, NPTX2, VGF, α-synuclein. All levels were Ln transformed. (C): Pearson r values for correlations between the three transformed marker levels for each diagnostic group independently. In the bottom table, the Pearson r values for the correlation to AD biomarkers and age are given. Color intensity indicates the strength of the correlation, with blue being stronger positive correlations and red stronger negative correlations. (D): ROC curve distinguishing between SCD and DLB. For all models, age was included. Markers combined is a model using NPTX2, VGF, and α-synuclein combined. AUCs and a significance value indicating if the significantly deviate for 0.5 are given.
Figure 1 NPTX2 levels and relation to biomarkers in CSF. (A): Levels of NPTX2 in CSF of SCD subjects and DLB and AD patients. Box-plots are median and interquartile ranges, whiskers are 95% percentiles. When significant, the p-value of Kruskal–Wallis with post-test is indicated. (B): 3D plot of the levels of the three related synaptic markers, NPTX2, VGF, α-synuclein. All levels were Ln transformed. (C): Pearson r values for correlations between the three transformed marker levels for each diagnostic group independently. In the bottom table, the Pearson r values for the correlation to AD biomarkers and age are given. Color intensity indicates the strength of the correlation, with blue being stronger positive correlations and red stronger negative correlations. (D): ROC curve distinguishing between SCD and DLB. For all models, age was included. Markers combined is a model using NPTX2, VGF, and α-synuclein combined. AUCs and a significance value indicating if the significantly deviate for 0.5 are given.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Johns Hopkins University (US)
  • University of Cagliari (IT)
Corresponding author
Boiten, Walter
Venue
Cells
Publisher
MDPI AG
Published
2020-12-29
Volume
10
Issue
1
Pages
38
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3117487831
Cited by
42
References
42
Citations by year
2026: 1 · 2025: 11 · 2024: 7 · 2023: 4 · 2022: 9 · 2021: 10
FWCI
4.20
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
ZonMw (733050509, 733050102)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
dementia with Lewy bodies, NPTX2, alpha-synuclein, VGF, cerebrospinal fluid biomarkers, synaptic loss, Alzheimer's disease, cognitive decline, visuospatial ability, GABAergic inhibition
MeSH terms
Pentraxins, Aged, C-Reactive Protein, Female, Humans, Male, Middle Aged, Nerve Growth Factors, Nerve Tissue Proteins, Cohort Studies, Biomarkers, Case-Control Studies, Lewy Body Disease, alpha-Synuclein, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.